Statement of Changes in Beneficial Ownership (4)
August 25 2016 - 8:04AM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue.
See
Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Loiacono Michael
|
2. Issuer Name
and
Ticker or Trading Symbol
TAPIMMUNE INC
[
TPIV
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director
_____ 10% Owner
__
X
__ Officer (give title below)
_____ Other (specify below)
Chief Financial Officer
|
(Last)
(First)
(Middle)
50 NORTH LAURA STREET, SUITE 2500
|
3. Date of Earliest Transaction
(MM/DD/YYYY)
8/25/2016
|
(Street)
JACKSONVILLE, FL 32202
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_
X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security
(Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code
(Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Table II - Derivative Securities Beneficially Owned (
e.g.
, puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 3)
|
2. Conversion or Exercise Price of Derivative Security
|
3. Trans. Date
|
3A. Deemed Execution Date, if any
|
4. Trans. Code
(Instr. 8)
|
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
6. Date Exercisable and Expiration Date
|
7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
|
8. Price of Derivative Security
(Instr. 5)
|
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)
|
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)
|
11. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
(A)
|
(D)
|
Date Exercisable
|
Expiration Date
|
Title
|
Amount or Number of Shares
|
Employee Stock Option (Right to Buy)
(1)
|
$0.475
|
8/25/2016
|
|
A
|
|
650000
|
|
(1)
|
8/25/2026
|
Common Stock
|
650000
|
$0.00
|
650000
|
D
|
|
Explanation of Responses:
|
(
1)
|
Represents options awarded under the Company's 2014 Omnibus Stock Ownership Plan in connection with the execution of Mr. Loiacono's employment agreement with the Company. 75,008 options shall vest immediately and the remaining options shall vest in 36 equal monthly installments of 15,972 options on the last day of each of the 36 months following the grant date. The option exercise price is the closing price on August 24, 2016 the trading day immediately prior to the award date.
|
Reporting Owners
|
Reporting Owner Name / Address
|
Relationships
|
Director
|
10% Owner
|
Officer
|
Other
|
Loiacono Michael
50 NORTH LAURA STREET, SUITE 2500
JACKSONVILLE, FL 32202
|
|
|
Chief Financial Officer
|
|
Signatures
|
/s/ Mark A. Catchur, as Attorney-in-Fact for Michael Loiacono
|
|
8/25/2016
|
**
Signature of Reporting Person
|
Date
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
|
*
|
If the form is filed by more than one reporting person,
see
Instruction 4(b)(v).
|
**
|
Intentional misstatements or omissions of facts constitute Federal Criminal Violations.
See
18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
|
Note:
|
File three copies of this Form, one of which must be manually signed. If space is insufficient,
see
Instruction 6 for procedure.
|
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
|
TapImmune, Inc. (NASDAQ:TPIV)
Historical Stock Chart
From Jul 2024 to Aug 2024
TapImmune, Inc. (NASDAQ:TPIV)
Historical Stock Chart
From Aug 2023 to Aug 2024
Real-Time news about Marker Therapeutics (delisted) (NASDAQ): 0 recent articles
More Tapimmune Inc News Articles